Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $55 | $1 | $0 | $0 |
| % Growth | 8,001.5% | – | – | – |
| Cost of Goods Sold | $8 | $0 | $1 | $1 |
| Gross Profit | $47 | $1 | -$1 | -$1 |
| % Margin | 85.6% | 75.5% | – | – |
| R&D Expenses | $34 | $50 | $71 | $72 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $291 | $118 | $100 | $62 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $325 | $168 | $172 | $135 |
| Operating Income | -$277 | -$167 | -$172 | -$135 |
| % Margin | -502.2% | -24,532.6% | – | – |
| Other Income/Exp. Net | -$57 | -$34 | -$25 | -$9 |
| Pre-Tax Income | -$334 | -$202 | -$198 | -$144 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$334 | -$202 | -$198 | -$144 |
| % Margin | -605.1% | -29,558.9% | – | – |
| EPS | -5.29 | -3.93 | -5.7 | -4 |
| % Growth | -34.6% | 31.1% | -42.5% | – |
| EPS Diluted | -5.29 | -3.93 | -5.7 | -4 |
| Weighted Avg Shares Out | 63 | 51 | 39 | 37 |
| Weighted Avg Shares Out Dil | 63 | 51 | 39 | 37 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15 | $8 | $2 | $0 |
| Interest Expense | $72 | $42 | $27 | $7 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$262 | -$159 | -$170 | -$137 |
| % Margin | -473.3% | -23,321% | – | – |